Trial · NCT01595321
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Limiting Toxicities | Cohort 1: SBRT and FOLFIRINOX | Diarrhea | 0 | Participants | |
| Dose Limiting Toxicities | Cohort 2: SBRT and Modified FOLFIRINOX | Diarrhea | 0 | Participants | |
| Dose Limiting Toxicities | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | Diarrhea | 1 | Participants | |
| Dose Limiting Toxicities | Cohort 1: SBRT and FOLFIRINOX | Neutropenia | 3 | Participants | |
| Dose Limiting Toxicities | Cohort 2: SBRT and Modified FOLFIRINOX | Neutropenia | 0 | Participants | |
| Dose Limiting Toxicities | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | Neutropenia | 1 | Participants | |
| Dose Limiting Toxicities | Cohort 1: SBRT and FOLFIRINOX | Thrombocytopenia | 2 | Participants | |
| Dose Limiting Toxicities | Cohort 2: SBRT and Modified FOLFIRINOX | Thrombocytopenia | 0 | Participants | |
| Dose Limiting Toxicities | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | Thrombocytopenia | 0 | Participants | |
| Grade 3 or Higher Cy/GVAX-related Adverse Events | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 2 | Participants | ||
| Overall Survival (OS) | Cohort 1: SBRT and FOLFIRINOX | 22.2 | 95% Confidence Interval 6.74 to NA | months | |
| Overall Survival (OS) | Cohort 2: SBRT and Modified FOLFIRINOX | 27.5 | 95% Confidence Interval 16.3 to NA | months | |
| Overall Survival (OS) | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 61.3 | 95% Confidence Interval 11.1 to NA | months | |
| Disease-free Survival (DFS) | Cohort 1: SBRT and FOLFIRINOX | 10.5 | 95% Confidence Interval 3.45 to NA | months | |
| Disease-free Survival (DFS) | Cohort 2: SBRT and Modified FOLFIRINOX | 14.5 | 95% Confidence Interval 10.1 to NA | months | |
| Disease-free Survival (DFS) | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 24.1 | 95% Confidence Interval 11.1 to NA | months | |
| Distant Metastases Free Survival (DMFS) | Cohort 1: SBRT and FOLFIRINOX | 10.5 | 95% Confidence Interval 3.45 to NA | months | |
| Distant Metastases Free Survival (DMFS) | Cohort 2: SBRT and Modified FOLFIRINOX | 19.0 | 95% Confidence Interval 10.15 to NA | months | |
| Distant Metastases Free Survival (DMFS) | Cohort 3: CY, GVAX, SBRT, and Modified FOLFIRINOX | 42.0 | 95% Confidence Interval 11.1 to NA | months | |
| Freedom From Local Progression (FFLP) | Cohort 1: SBRT and FOLFIRINOX | 17.3 | 95% Confidence Interval 6.74 to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01595321/results